Condition category
Mental and Behavioural Disorders
Date applied
07/12/2006
Date assigned
28/12/2006
Last edited
02/04/2008
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Aysegul Yildiz-Yesiloglu

ORCID ID

Contact details

McLean Hospital
Brain Imaging Center
115 Mill Street
Belmont
MA 02478
United States of America
+1 781 281 0395
agul_yildiz@hotmail.com

Additional identifiers

EudraCT number

ClinicalTrials.gov number

NCT00411203

Protocol/serial number

AY0001

Study information

Scientific title

Acronym

Mania-Tamoxifen Trial

Study hypothesis

1.There will be greater reduction in ratings of manic or mixed mood symptoms with tamoxifen citrate compared to placebo.
2.A greater proportion of subjects will respond to tamoxifen citrate when compared to placebo.

Ethics approval

The study was approved by the Turkish Ministry of Health, General Directorate of Drugs and Pharmaceutics, Central Review Board, and Local Ethical Committee of Drug Investigations at the Dokuz Eylul University.

Study design

Randomised, controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Treatment

Patient information sheet

Condition

Bipolar Disorder-I, most recent episode manic or mixed, with or without psychotic features

Intervention

Subjects were recruited from the local community, an urban area in the western part of Turkey, surrounding suburbs, and towns as well as all over the country (expert-seeking patients who reached the principle investigator [PI] via the internet and news media) between April, 2003 and June, 2006. All diagnoses were based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV), administered by a trained investigator. After the protocol explained to the patient and at least one first degree relative, both gave written informed consent for participation of the patient in the trial. Subject screening included medical and psychiatric history, physical examination, and laboratory screen including Liver Function Tests (LFTs), Thyroid Stimulating Hormone (TSH), Human Chorionic Gonadotropin (HCG), Blood Urea Nitrogen (BUN), Creatinine, and serum toxicology. All psychotropic medication (except benzodiazepines) was discontinued at least one day before randomisation.

Subjects entering the study were randomly assigned to receive the Protein Kinase C (PKC) inhibitor, tamoxifen or identical placebo tablets in a 1:1 ratio and double-blind fashion for three weeks. Computer-generated codes were used to create randomisation kits (prepared by the ARGEFAR, a contract research organization). The starting dose of tamoxifen was 20 mg twice daily (bid). After the first treatment day, daily dose was adjusted upward by 10 mg per day up to 80 mg/d in divided doses. Similar tablet adjustments were applied for the patients in placebo group. Concomitant use of oral lorazepam (2.5 mg dissolving tables) was allowed during double-blind therapy as clinically indicated.

In cases where lorazepam is thought to be ineffective and the symptoms are such that an antipsychotic is required, risperidone liquid formulations (2-6 mg/day) were used under emergency circumstances. Those subjects who were given risperidone were assumed as drop out at the time of first exposure to risperidone; and new subjects for replacement of those cases have been recruited. Yet, the subjects who volunteer to continue study drug, assessed weekly without opening blind and data on combined use of open label risperidone and blind tamoxifen is presented in a separate section. Subjects were seen twice daily and investigators were on call 24 hours a day.

Intervention type

Drug

Phase

Not Specified

Drug names

Tamoxifen citrate, lorazepam, Protein Kinase C (PKC) inhibitor, risperidone

Primary outcome measures

Assessment tools:
1. Young Mania Rating Scale (YMRS)
2. Hamilton Depression Rating Scale-17 item (HAMD-17)
3. Montgomery-Asberg Depression Rating Scale (MADRS)
4. Clinical Global Impressions-Bipolar Version of Severity of Illness (CGI)
5. Positive and Negative Syndrome Scale (PANSS) and side effect questionnaire

These were administered by semi-structured interviews at each week. Vital signs and weight were monitored. The PI, who is trained in the rating instruments and blind to the treatment condition (training and certification at the Massachusetts Hospital, Bipolar Program), performed all the study assessments on a weekly basis. The primary efficacy variable is defined as the reduction from baseline of the YMRS score after three weeks of therapy. Positive treatment response was defined as a more than 50% decrease in YMRS from baseline to three weeks.

Added as of 18/04/2007:
Analyses of all the primary and secondary outcomes were performed under the intent-to-treat principle based on normal linear mixed effect models based on all 66 randomised participants and all observations up until the time of drop out. Patients who initiated risperidone and dropped the study were included in the primary intent-to-treat analysis with their outcome scores censored at time of risperidone initiation.

Secondary outcome measures

The secondary outcome measures were the reductions from baseline of the PANSS and CGI Mania scores after three weeks of therapy.

Overall trial start date

02/04/2003

Overall trial end date

30/06/2006

Reason abandoned

Eligibility

Participant inclusion criteria

1. Diagnosis of Bipolar Disorder (BD I), most recent episode, manic or mixed
2. Aged 18 to 65
3. Young Mania Rating Scale (YMRS) score more than 20 at screening and baseline
4. Providing written informed consent

Participant type

Patient

Age group

Adult

Gender

Not Specified

Target number of participants

50

Participant exclusion criteria

1. Currently pregnant, planning to become pregnant, or breast feeding
2. History of any coagulopathies, deep vein thrombosis, pulmonary embolus
3. A history of hypersensitivity to tamoxifen
4. Drug screen positive for any drug of abuse at screening, active substance abuse in the past two weeks or substance dependence in the past two months (except nicotine and caffeine)
5. Diagnosis of schizophrenia, dementia, delirium, seizure disorder, obsessive compulsive disorder, or major cardiac, hepatic or renal disease that is unstable or that requires medical care
6. Administration of any other investigational drug in the last 30 days
7. Clinically significant suicidal or homicidal ideation

Recruitment start date

02/04/2003

Recruitment end date

30/06/2006

Locations

Countries of recruitment

Turkey

Trial participating centre

McLean Hospital
Belmont
MA 02478
United States of America

Sponsor information

Organisation

The Stanley Medical Research Institute (SMRI) (USA)

Sponsor details

c/o Chevy Chase
MD
8401 Connecticut Ave
Suite 200
Chevy Chase
20815
United States of America

Sponsor type

Research organisation

Website

http://www.stanleyresearch.org

Funders

Funder type

Research organisation

Funder name

Stanley Medical Research Institute (SMRI) (USA) (Grant ID: 02T-162A)

Alternative name(s)

SMRI

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United States of America

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Results in http://www.ncbi.nlm.nih.gov/pubmed/18316672

Publication citations

  1. Results

    Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF, Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen., Arch. Gen. Psychiatry, 2008, 65, 3, 255-263, doi: 10.1001/archgenpsychiatry.2007.43.

Additional files

Editorial Notes